trazodone has been researched along with Chemical Dependence in 19 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The result of the search of drugs that help people to alcoholism treatment program, were studies involving trazodone." | 4.87 | [Trazodone in the treatment of addiction]. ( Bobińska, K; Florkowski, A; Gałecki, P; Kryszkowski, W; Orzechowska, A; Talarowska, M, 2011) |
| "From this review, it is concluded that there are very few data to suggest that trazodone improves sleep in patients without mood disorder, though it does increase total sleep in patients with major depressive disorder." | 4.82 | The use of trazodone as a hypnotic: a critical review. ( James, SP; Mendelson, WB, 2004) |
| "Priapism is a serious urological and a medical emergency which has often been associated with psychotropic medications (including the antidepressant trazodone), use of marijuana and alcohol, and other factors." | 1.43 | Priapism: What cause: mental illness, psychotropic medications or poly-substance abuse? ( Khan, QS; Lokhande, A; Tucker, P, 2016) |
| " Some participants expressed concern at the lack of data for this practice, particularly the absence of dose-response and tolerance information, and noted that the small amount of efficacy data available is not encouraging." | 1.32 | The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. ( Buysse, DJ; Cassella, J; Mendelson, WB; Meyer, RE; Roehrs, T; Roth, T; Walsh, JK; Woods, JH, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (21.05) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 6 (31.58) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Mazza, M | 1 |
| Caroppo, E | 1 |
| Marano, G | 1 |
| Kotzalidis, GD | 1 |
| Avallone, C | 1 |
| Camardese, G | 1 |
| Janiri, D | 1 |
| Moccia, L | 1 |
| Simonetti, A | 1 |
| Janiri, L | 1 |
| Sani, G | 1 |
| Khan, QS | 1 |
| Tucker, P | 1 |
| Lokhande, A | 1 |
| Funk, S | 1 |
| Mendis, SB | 1 |
| Lukats, V | 1 |
| Apgar, BS | 1 |
| Logan, BK | 1 |
| Costantino, AG | 1 |
| Rieders, EF | 1 |
| Sanders, D | 1 |
| Baron, JM | 1 |
| Griggs, DA | 1 |
| Nixon, AL | 1 |
| Long, WH | 1 |
| Flood, JG | 1 |
| Kryszkowski, W | 1 |
| Bobińska, K | 1 |
| Talarowska, M | 1 |
| Orzechowska, A | 1 |
| Florkowski, A | 1 |
| Gałecki, P | 1 |
| Mendelson, WB | 2 |
| Roth, T | 1 |
| Cassella, J | 1 |
| Roehrs, T | 1 |
| Walsh, JK | 1 |
| Woods, JH | 1 |
| Buysse, DJ | 1 |
| Meyer, RE | 1 |
| James, SP | 1 |
| Rachid, F | 1 |
| Golaz, J | 1 |
| Bondolfi, G | 1 |
| Bertschy, G | 1 |
| Ansseau, M | 1 |
| De Roeck, J | 1 |
| Craig, RJ | 1 |
| Rush, CR | 1 |
| Baker, RW | 1 |
| Wright, K | 1 |
| Schenck, CH | 1 |
| Mahowald, MW | 1 |
| Piccione, M | 1 |
| Laguardia, S | 1 |
| Liebowitz, NR | 1 |
| el-Mallakh, RS | 1 |
| Gamble, DE | 1 |
| Peterson, LG | 1 |
| Small, GW | 1 |
| Purcell, JJ | 1 |
3 reviews available for trazodone and Chemical Dependence
| Article | Year |
|---|---|
[Pharmacological treatment in alcohol-, drug- and benzodiazepine-dependent patients - the significance of trazodone].
Topics: Alcoholism; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Benzodiazepines; Cardiova | 2013 |
[Trazodone in the treatment of addiction].
Topics: Alcoholism; Behavior, Addictive; Humans; Selective Serotonin Reuptake Inhibitors; Substance-Related | 2011 |
The use of trazodone as a hypnotic: a critical review.
Topics: Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Comorbidity; Depressive Disorder; Humans; Hypn | 2004 |
1 trial available for trazodone and Chemical Dependence
| Article | Year |
|---|---|
Trazodone in benzodiazepine dependence.
Topics: Adult; Ambulatory Care; Benzodiazepines; Drug Administration Schedule; Female; Hospitalization; Huma | 1993 |
15 other studies available for trazodone and Chemical Dependence
| Article | Year |
|---|---|
Trazodone Prolonged-Release Monotherapy in Cannabis Dependent Patients during Lockdown Due to COVID-19 Pandemic: A Case Series.
Topics: Cannabis; Communicable Disease Control; COVID-19; COVID-19 Drug Treatment; Female; Hallucinogens; Hu | 2022 |
Priapism: What cause: mental illness, psychotropic medications or poly-substance abuse?
Topics: Adrenergic alpha-1 Receptor Antagonists; Depressive Disorder, Major; Hepatitis C; Humans; Male; Midd | 2016 |
Diagnostic conundrum: lessons from the man who accidently set fire to his home.
Topics: Accidents; Brain Injuries, Traumatic; Executive Function; Fires; Hepatitis C, Chronic; Housing; Huma | 2016 |
Challenges of fragmented care in long-term management of pelvic pain.
Topics: Acetaminophen; Adult; Amines; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Anxiety Agents; Chr | 2007 |
Trazodone, meta-chlorophenylpiperazine (an hallucinogenic drug and trazodone metabolite), and the hallucinogen trifluoromethylphenylpiperazine cross-react with the EMIT®II ecstasy immunoassay in urine.
Topics: Antidepressive Agents; Cross Reactions; False Positive Reactions; Hallucinogens; Humans; Illicit Dru | 2010 |
The trazodone metabolite meta-chlorophenylpiperazine can cause false-positive urine amphetamine immunoassay results.
Topics: Amphetamine; Anti-Anxiety Agents; False Positive Reactions; Humans; Immunoassay; Piperazines; Substa | 2011 |
The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Depressive Disorder, Major; Dose-Response | 2004 |
Induction of a mixed depressive episode during rTMS treatment in a patient with refractory major depression.
Topics: Adult; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive | 2006 |
Urine screening for drugs and trazodone.
Topics: Amphetamine; Enzyme Multiplied Immunoassay Technique; False Positive Reactions; Humans; Substance Ab | 1996 |
Acute behavioral effects and abuse potential of trazodone, zolpidem and triazolam in humans.
Topics: Adult; Antidepressive Agents, Tricyclic; Humans; Hypnotics and Sedatives; Male; Memory; Mental Recal | 1999 |
Combined bupropion-levodopa-trazodone therapy of sleep-related eating and sleep disruption in two adults with chemical dependency.
Topics: Adult; Antidepressive Agents, Second-Generation; Antiparkinson Agents; Bupropion; Depressive Disorde | 2000 |
[Studies on drug dependence : trazodone].
Topics: Adolescent; Adult; Antidepressive Agents; Female; Humans; Male; Middle Aged; Piperazines; Substance- | 1975 |
Trazodone for the treatment of anxiety symptoms in substance abusers.
Topics: Adult; Alcoholism; Anxiety Disorders; Combat Disorders; Humans; Male; Middle Aged; Sleep Initiation | 1989 |
Trazodone overdose: four years of experience from voluntary reports.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Ethanol; Female; Humans; Male; Middle Age | 1986 |
Trazodone and cocaine abuse.
Topics: Adult; Cocaine; Humans; Male; Piperazines; Substance Withdrawal Syndrome; Substance-Related Disorder | 1985 |